Abstract:
EntreMed, Inc. today announced that it has entered into a Clinical Supply Agreement with Elan Drug Delivery, Inc. to reformulate and manufacture EntreMed's Panzem(R) in an oral liquid product format. This supply of reformulated Panzem(R) will support EntreMed's clinical oncology program that is planned to begin in early 2005. Elan is manufacturing the reformulated Panzem(R) using its proprietary NanoCrystal(R) technology that enhances product bioavailability and absorption and produces particles that are fifty times smaller than conventional processes.